Table 1.

Tumor Histologic Types, Sites of Disease, and Mutations Identified in Thyroid Cancers

Patient a	Sample ID b	Diagnosis	Mutation c	Sites of Disease	Mutation Testing Location
1	01-007	FTC	HRAS Q61R	Lung, mediastinum	Asuragen
2	02-008	FTC	HRAS Q61R	Bone, lung	Asuragen
3	01-002	FTC	NRAS Q61K	Bone, lung	Asuragen
4	01-012	FTC	NRAS Q61R	Lung	Interpace Diagnostics
5	02-015	FTC	NRAS Q61R	Bone, lung	Interpace Diagnostics
6	03-002	FTC	NRAS Q61R	Bone, brain, liver, lung, pleura	Asuragen
7	03-004	FTC	NRAS Q61R	Lung, mediastinum	Asuragen
8	04-002	FTC	NRAS Q61R	Bone, lung	Interpace Diagnostics
9	04-003	FTC	NRAS Q61R	Lung	Interpace Diagnostics
10	02-005	FTC	None	Bone, lung, mediastinum	Asuragen
11	02-006	FTC	None	Brain, lung, neck, skin	Asuragen
12	03-003	FTC	None	Lung, mediastinum	Asuragen
13	04-001	FTC	None	Lung	Interpace Diagnostics
14	04-004	FTC	None	Lung, neck	Interpace Diagnostics
15	04-005	FTC	None	Neck	Interpace Diagnostics
16	01-003	FTC	no PPFP	Bone, lung	University of Michigan
17	01-004	FTC	no PPFP	Bone, liver	University of Michigan
18	02-012	FVPTC	BRAF V600E	Bone, lung	Asuragen
19	02-013	FVPTC	BRAF V600E	Lung, mediastinum	Interpace Diagnostics
20	02-014	FVPTC	BRAF V600E	Lung, mediastinum	Interpace Diagnostics
21	02-002	FVPTC	HRAS Q61K	Lung, mediastinum	Asuragen
22	01-013	FVPTC	HRAS Q61R	Lung	Interpace Diagnostics
23	02-003	FVPTC	NRAS Q61K	Lung	Asuragen
24	01-009	FVPTC	NRAS Q61R	Lung	Asuragen
25	01-011	FVPTC	NRAS Q61R	Adrenal, bone, brain, lung, mediastinum, neck	Interpace Diagnostics
26	04-006	FVPTC	None	Lung, mediastinum	Interpace Diagnostics
27	01-001	FVPTC	No PPFP	Bone, liver, lung, mediastinum, neck	University of Michigan
28	01-005	FVPTC	No PPFP	Lung	University of Michigan
29	01-006	Hürthle	PPFP	Bone	Asuragen
30	01-010	Hürthle	None	Bone, lung	Asuragen
31	01-008	Hürthle	None	Lung, mediastinum, neck	Asuragen
32	02-001	Hürthle	None	Bone, lung, mediastinum	Asuragen
33	02-009	Hürthle	None	Lung, neck	Asuragen
34	02-010	Hürthle	None	Bone	Interpace Diagnostics
35	02-011	Hürthle	None	Abdomen lymph node, liver	Asuragen
36	02-004	Insular	NRAS Q61K	Bone, lung	Asuragen
37	01-014	Poorly differentiated and PTC	HRAS Q61K	Bone, lung	Interpace Diagnostics
38	02-007	PTC	NRAS Q61K	Lung, mediastinum	Asuragen
39	03-001	PTC	NRAS Q61R	Adrenal, bone, lung, neck	Asuragen
40	01-015	PTC	None	Lung	Interpace Diagnostics

^aPatients are sorted by histologic diagnosis and mutation.

^bSample IDs are numbered sequentially by order of screening at each site [(01) University of Michigan Comprehensive Cancer Center (02) University of Colorado Comprehensive Cancer Center (03) Ohio State University Comprehensive Cancer Center (04) University of Texas MD Anderson Cancer Center].

^c"None" signifies no mutation detected in BRAF, HRAS, KRAS, NRAS, RET/PTC1, RET/PTC3, or PPFP. Testing at the University of Michigan was only for PPFP. See "Clinical Trial and Case Report" section for additional information.